Mycenax Biotech Inc. (TPEX:4726)

Market Cap	7.40B
Revenue (ttm)	725.45M
Net Income (ttm)	-460.65M
Shares Out	207.11M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	483,008
Average Volume	172,207
Open	35.75
Previous Close	35.75
Day's Range	34.30 - 36.30
52-Week Range	27.40 - 55.50
Beta	0.51
RSI	30.01
Earnings Date	Aug 12, 2025

About Paramount Global

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2024, Mycenax Biotech's revenue was 683.92 million, an increase of 4.80% compared to the previous year's 652.62 million. Losses were -467.13 million, -31.59% less than in 2023.